Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 chimeric antigen receptor T cell therapy - The Beijing Pregene Science and Technology Company

Next Previous
Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - The Beijing Pregene Science and Technology Company

Alternative Names: CART-19 cells - Beijing Pregene Science and Technology Company; CD19 specific chimeric antigen receptor T-cells - Beijing Pregene Science and Technology Company

Latest Information Update: 25 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Pregene Science and Technology
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in B-cell lymphoma(In the elderly, Second-line therapy or greater, In adults) in China (IV)
  • 01 Aug 2017 Phase-I/II clinical trials in Acute lymphoblastic leukaemia (In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in China (Parenteral) (NCT03263208)
  • 01 May 2017 Phase-I/II clinical trials in B-cell lymphoma (In the elderly, Second-line therapy or greater, In adults, Adjunctive treatment, Refractory metastatic disease) in China (IV) (NCT03146533)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top